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Background: Several international forums for promoting clinical pharmacology in developing countries have been
held since 1980, and several clinical pharmacology programmes targeting developing countries were instituted
such that the status of clinical pharmacology in developing countries is not where it was 50 years ago. Therefore,
a survey and an appraisal of the literature on the current status of clinical pharmacology in developing countries
were undertaken with a hope that it would enable development of appropriate strategies for further promotion
of clinical pharmacology in these countries.
Methods: First, nine determinants (or enabling factors) for running a successful clinical pharmacology programme
were identified, i.e., disease burden, drug situation, economic growth, clinical pharmacology activities, recognition,
human capital, government support, international collaboration, and support for traditional/alternative medicines.
These factors were then evaluated with regard to their current status in the developing countries that responded
to an electronic questionnaire, and their historical perspective, using the literature appraisal. From these, a projected
trend was constructed with recommendations on the way forward.
Results: Clinical pharmacology services, research and teaching in developing countries have improved over the
past 50 years with over 90% of countries having the appropriate policies for regulation and rational use of
medicines in place. Unfortunately, policy implementation remains a challenge, owing to a worsening disease
burden and drug situation, versus fewer clinical pharmacologists and other competing priorities for the national
budgets. This has led to a preference for training ‘a physician clinical pharmacologist’ in programmes emphasizing
local relevancy and for a shorter time, and the training of other professionals in therapeutics for endemic diseases
(task shifting), as the most promising strategies of ensuring rational use of medicines.
Conclusion: Clinical pharmacology in developing countries is advancing in a different way to that in the
developed world and continuing support for these efforts will go a long way in promoting improved health for all.
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World Health OrganisationBackground
The need for special focus on clinical pharmacology in
developing countries was expressed in several workshops
at the first World Congress of Clinical Pharmacology
in 1980, and later by Fraser in 1981 [1,2]. Soon after,
another international forum aimed at promoting clinical
pharmacology in developing countries was held in 1984
under the auspices of the IUPHAR and the Clinical
Section of the British Pharmacological Society [3]. ThisCorrespondence: waluboa@ufs.ac.za
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reproduction in any medium, provided the orwas followed by several communications as well as
physical meetings by different stakeholders including
IUPHAR and the World Health Organisation (WHO).
Wide ranging proposals were made with regard to
training, research and service in clinical pharmacology
in developing countries by the developed world, including
private industry. Since then, several clinical pharmacology
programmes targeting developing countries have been
instituted [4-8]. These clinical pharmacology programmes
were augmented by developments in other sectors par-
ticularly economic growth that enabled the construction
of essential facilities such as medical schools. TheseThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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programmes on clinical pharmacology by the international
community, and many graduates from these institutions
have used them as spring boards to further training in
clinical pharmacology in the developed countries. Un-
fortunately, despite such investment, reports on clinical
pharmacology in developing countries over the past
50 years have been characterized by the same tone,
gloomy: i.e., the discipline still remains in infancy, and
that the need for clinical pharmacology here is bigger
than anywhere else [1-3,9-11].
In response to such reports, the IUPHAR’s division of
clinical pharmacology, through its subcommittee on ‘clin-
ical pharmacology in the developing countries’, embarked
on a mission to make visible progress in the development
of clinical pharmacology in these countries. Accordingly,
the status of clinical pharmacology in developing countries
was a subject of a focus conference at the World Congress
of Pharmacology 2010 in Copenhagen, in which various
speakers expressed their opinions. Again, it was clear
that the status of clinical pharmacology in developing
countries was not where it was 50 years ago, and that
its development had not followed the same path as in
the developed world. Later, in its subsequent meeting,
the same IUPHAR subcommittee expressed the need
for an accurate report on the current status of clinical
pharmacology in developing countries, as a pre-requisite
to development of appropriate strategies for promotion
of clinical pharmacology in these countries.
Unfortunately, most of the information on clinical
pharmacology in developing countries is not available in
the main stream literature. It is contained in different
communications, mainly experts’ reports, for organisations
such as the WHO, where it has not been associated
with clinical pharmacology. Secondly, these reports are
often so detailed and address a variety of multidisciplinary
issues such that they are often not suitable for publication
in a scientific journal. Here is presented a pragmatic report
on the current status of clinical pharmacology in devel-
oping countries based on information obtained by a
survey on clinical pharmacology activities in some of the
developing countries, supplemented by a comprehensive
appraisal of the literature. It is hoped that this information
will enable formulation of appropriate interventions
to foster rational use of medicines in the developing
countries.
Methods
Nine factors were identified as the major determinants
(or enabling factors) for running a successful clinical
pharmacology programme. They were: the disease burden,
the drug situation, economic growth, clinical pharmacol-
ogy activities (training, research and service), recogni-
tion of clinical pharmacology, human capital (clinicalpharmacologists and affiliated personnel), local or gov-
ernment support, international support/collaboration and
support for traditional/alternative medicines. A survey
was undertaken to assess the status and/or existence of
some of these enabling factors with a hope that their
status would form a useful index for measuring the
state of clinical pharmacology at any point in time. The
study was approved by the Ethics Committee of University
of the Free State (ECUFS ref: 148/2013).
This was a one page questionnaire. After a successful
piloting in three institutions, the questionnaire was
distributed electronically (by e-mail) worldwide to heads
of departments of pharmacology with a help of regional
volunteers in Asia, L. America and, Eastern Europe and
Africa. It took approximately 15–20 min to complete
the questionnaire. Developing countries were deter-
mined according to the United Nations Development
Programme (UNDP) and World Bank classification of
countries [12,13].
Respondents were asked whether clinical pharmacology
is a recognised specialty in their country, and if yes, to
name the certifying body. It also sought to know
whether the respective institution had a dedicated clinical
pharmacology department or unit, and if so, the number
of professionals serving as clinical pharmacologists and
their respective qualifications, i.e., the number of pharma-
cologists with M.B.Ch.B. and B. Pharm. or equivalent, as
well as those with a Ph.D. or equivalent. The questionnaire
also probed for presence of scientific forums for pharma-
cologists, such as a pharmacology society or other, and
how often it holds conferences. For information on clinical
pharmacology services, respondents were asked to indi-
cate the main clinical pharmacology services undertaken
at their departments/units by selecting from a given list,
i.e., research, undergraduate teaching, research (clinical
trials), postgraduate training, pharmacovigilance, drug
utilization, therapeutic patient care/consultation, drug
policy or drug regulation, poison information service and
other. Respondents were asked to indicate the affiliated
personnel with whom the clinical pharmacologists worked
(staff members of the units/departments), i.e., medical
doctors, pharmacists, nurses, laboratory personnel, poison
information officers and others. Regarding training, the
questionnaire sought for whether the respective clinical
pharmacology departments or units undertake undergra-
duate and postgraduate training in clinical pharmacol-
ogy, and for the latter, what qualification was awarded
to these graduates, i.e., M.Sc., Ph.D., D.M., M. Med,
F.C.P., D.Sc., Dip. The questionnaires also asked whether
the institution had adequate number of patients and the
disease profile to enable adequate training of clinical
pharmacologists, and whether the institution had the
appropriate drugs to meet its patient requirements. For
those countries that had a drug regulatory authority,
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satisfied with the effectiveness of the respective drug
regulatory authority, and what fraction (percentage) of
drugs on market were made locally versus those
imported.
Data was captured on an Excel® data sheet, where the
responses were coded and summarised as a percentage
of respondents that answered a specific question in a
similar way. The result was reported for each status of
enabling factors for running a successful clinical pharma-
cology programme that was evaluated, i.e., clinical
pharmacology training, recognition of clinical pharmacol-
ogy, human capital: clinical pharmacologists and affiliated
personnel, local support (government) and international
support.
Literature review
Because some aspects of the enabling factors could not
reasonably be determined by the survey, particularly the
historical perspectives, information from the literature
and relevant experts’ reports from agencies such as
WHO and UNAIDS (United Nations Programme on
HIV/AIDS), were used to supplement the survey. This
was also important for determination of ‘trends in clinical
pharmacology’.
Results
Of the 52 institutions approached, there were 21 respon-
dents (40.4%) despite repeated reminders, i.e., Africa (11),
Asia (8), Latin America (3) and Easter Europe (0). They
comprised of medical schools (12), pharmacy schools (6),
contract research organizations (2) and hospitals (1).
Fortunately all the responses could be utilised.
Regarding the professional background of staff members
serving as clinical pharmacologists, 34.5% of respon-
dents indicated they had medical graduates (i.e., with M.B.
Ch.B. or equivalent), 32.7% had pharmacy graduates, and
altogether 38% of the medical and pharmacy graduates
had Ph.D. or equivalent. These clinical pharmacologists
worked with other personnel in their teams whereby
66.7% of the respondents indicated they had medical offi-
cers, 60% had pharmacists, 60% had laboratory personnel,
40% had nurses, and only 13.3% had poison information
officers (Figure 1A).
Figure 1B illustrates the on-going clinical pharmacology
activities in the study sample. There was wide variation
in the clinical pharmacology activities and qualifications
offered by different institutions, even from within the
same country. Regarding clinical pharmacology services,
40% of respondents undertook bedside patient consult-
ation, 53.3% had a pharmacovigilance programme, 20%
offered medical & poison information services, and 40%
participated in drug policy formulation or drug regulation.
Regarding clinical pharmacology research, the majority(93.3%) of respondents undertook research, but only 66.7%
were doing clinical trials (or drug development clinical
research), while 53.3% participated in drug utilization
studies, and only 13.3% had international collaborative
research projects. On clinical pharmacology training,
87% offered undergraduate training, while 60% offered
post-graduate training in both basic and/or clinical
pharmacology, with only 25% indicating they undertook
postgraduate training in clinical pharmacology. Interest-
ingly, there was wide variation in the names or codes used
for the postgraduate qualifications in pharmacology and/
or clinical pharmacology (M. Sc., Ph.D., D.M., M. Med,
F. clinical pharmacology, D.Sc., Dip.), such that it was
difficult to determine a basic and clinical pharmacology
qualification by the code. In effect, there was no standard
qualification for a Clinical Pharmacologist in developing
countries.
Figure 1C reflects on the drug situation, whereby only
40% of respondents indicated they had the appropriate
number and variety of drugs to meet their patients’ re-
quirements, and that 66% of these drugs were imported.
Furthermore, of the 96.3% who indicated that they had a
national Drug Regulatory Authority, 46.7% indicated that
it was ineffective. These results reflect a situation of
chronic drug shortage in the developing countries.
On clinical pharmacology recognition and local support
(Figure 1D), 53.3% of respondents indicated that clinical
pharmacology is recognised as a specialty by their govern-
ments, but, within the institutions, only 40% indicated
that they had a dedicated clinical pharmacology division
or department. Furthermore, lack of visibility of clinical
pharmacology was indicated by the few forums for clinical
pharmacology knowledge exchange, whereby only 7%
had Colleges of Clinical Pharmacologists and only 27%
indicated that clinical pharmacology is part of their
national pharmacology society that meets annually.
Discussion
In general, the survey has articulated the status of the
drug situation, clinical pharmacology activities, and extent
of recognition and local support for clinical pharmacology
in the developing countries. The response rate of 40.4% to
the electronic questionnaire was within the expected range
of 33.4 ± 9.4% for online surveys, in general [14], and was
better than in a previous report on clinical pharmacology
in developing countries [15]. Although most of the
respondents were from Africa, confining the report to
Africa would lead to loss of the contribution by the
other half of the respondents, which countries have a
lot in common with African countries of similar socio-
economic categorization. Furthermore, the categorization
of the responding institutions into medical and pharmacy
schools, etc., was to emphasize that clinical pharmacolo-






























































































Figure 1 Enabling factors for clinical pharmacology. An Illustration of the proportion (%) of respondents regarding: composition of the
personnel (A), clinical pharmacology activities (B), drug situation (C) and clinical pharmacology recognition (D). Key: A: Drs =medical officers;
Lab = laboratory personnel; Other = other health workers. Pharms = pharmacists; P-officers = poison information officers; B: Consult = consultations;
D/util. = drug utilization; D-policy = drug policy; Other = other services; P/vig = pharmacovigilance; Poisons = poison information services; Post-gr. =
post graduate training; Res = research; Trials = clinical trials; U-gra-T = undergraduate training; C: D-imported =most drug are imported; DRA = have a
drug regulatory authority; Drugs = drugs meet patient requirements; Eff-DRA = ineffective DRA; Pats = had appropriate mix of patients for training
purposes; D: College-CP = had a College of Clinical pharmacologists; CP-unit/dept = had a clinical pharmacology unit/department; Govt-recog = Clinical
pharmacology recognised by government; P/society = had a pharmacology society.
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Table 1 Developing countries that had a ‘clinical
pharmacology forum’ separate or part of the broad
national pharmacology society by 2007
AFRICA L - AMERICA ASIA E - EUROPE
Egypt Argentina China Bosnia & Herzegovina
Kenya Brazil Indian Bulgaria
South Africa Chile Indonesian Croatia











Key: L-America = Latin America; E-Europe = Eastern Europe.
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should be regarded as preliminary hoping for confirmation
in a larger study. Also, during the preparation of this
manuscript, it emerged that the European Association
of Clinical Pharmacology and Therapeutics (EACPT)
has undertaken a study on clinical pharmacology in
Europe but most of this has been communicated only
at its congresses.
Clinical pharmacology activities
Clinical pharmacology activities include clinical pharma-
cology services, training and research. The scope of these
activities is well explained in the recent WHO handbook
and the IUPHAR position statement on clinical pharma-
cology in health care, research and teaching [16,17].
Nevertheless, whereas the two resources are appropriate
for understanding the role of clinical pharmacology in
health care, research and teaching, they don’t illustrate
the scale to which these activities are running, and how
much more is needed.
From the survey, it is clear that training and research
were the major functions of the clinical pharmacologists
in the respondent’s institutions. However, the survey could
not determine whether the training was in clinical or basic
pharmacology. The challenges of clinical pharmacologists
in the developing countries include being trained from
overseas in programmes with limited local content or
relevancy, lack of appropriate clinical pharmacology train-
ing resources that appeal to the conditions in developing
countries, limited incentives to clinical pharmacology
training, and lack of close partnerships and collaboration
among clinical pharmacologists in the developing coun-
tries. There is more collaboration with overseas institu-
tions than amongst themselves.
Human capital
Lack of expertise is one of the biggest contributing
factors to the poor clinical pharmacology services in
the developing world. Worse still, human capital in any
organisation is so dynamic that the results of this 2010-
survey may not reflect the reality. Nevertheless, one can
confidently say that, even though there was no recognition
or accreditation for clinical pharmacologists in most of
the developing countries, there is a small pool of clinical
pharmacologists working in these countries. There is a
need to organise these individuals into a regional or
continental professional body that can be used to promote
their plight.
Recognition of clinical pharmacology and local support
Recognition and local support for clinical pharmacology
by government refers to the creation of posts and a career
path for clinical pharmacologists, while recognition by the
host institution gives the discipline a distinction indicatedby presence of a clinical pharmacology department or unit
in the respective institution. On the other hand, creation
of a college of clinical pharmacologists ensures appropri-
ate professional conduct, while forums such as clinical
pharmacology society are important not only for sharing
scientific information but also for advocacy.
Recognition by governments and professional visibility:
Our search showed that by 2007, 84.8% (22/26) of the
Eastern Europe countries had successfully recognised
clinical pharmacology as a specialty. Furthermore, of the
26 countries in Easter Europe, 14 (50%) had a clinical
pharmacology forum or society (Table 1). This was in
sharp contrast to Africa where, of the 52 countries, only
5 (9.6%) had a pharmacology society. Even then, South
Africa was the only country where clinical pharmacology
was recognized as a specialty [18]. Of note, West African
countries have opted for a regional society, the West
Africa Pharmacology Society, which is dominated by
Nigeria and Ghana. In Asia, of the 26 countries, 8 (31%)
had a pharmacology society, and only three (Philippines,
India and Thailand) had recognized clinical pharmacology
as a specialty. In Latin America, of the 18 countries, 7
(39%) had a pharmacology society, and none recognized
clinical pharmacology as a specialty. This poor rate of
recognition as a specialty was also reflected in the survey.
It must be pointed out that government’s recognition
and local support for any speciality precedes the devel-
opment of ‘human capital’ in that speciality. As such, it
is only when a government recognises clinical pharma-
cology as a speciality that it creates an obligation to meet
the training and employment needs of clinical pharmacol-
ogists. Unfortunately, although some governments have
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ernments are unwilling to do so owing to the contending
priorities that supersede requirements for upcoming spe-
cialities such as clinical pharmacology. Nevertheless, ap-
propriate local support should go beyond recognition by
way of proclamation. Clinical pharmacology ought to be
included in the competing priorities for national and insti-
tutional budgets aimed at establishing any facilities for
health service, research and training.
International support
Developing countries have received considerable support
from the international community for different purposes,
and clinical pharmacology has been one of the main
beneficiaries. The support ranges from sponsoring indi-
viduals to further their education and training overseas,
and funding research capacity strengthening programmes,
to direct intervention in running clinical pharmacology
services by organisation such as the WHO, USP (United
States Pharmacopeia), UNAIDS, to mention but a few.
However, the IUPHAR and WHO, through their specialist
divisions, remain the major advocates for clinical pharma-
cology development in the world.
Also, clinical pharmacology training opportunities have
been offered in several countries: United Kingdom, United
States of America, the Nordic Countries, Belgium, France,
Germany, Australia, etc., and most of these have extensive
collaborative Research Programmes with the many de-
veloping countries; i.e., the North–south collaboration
through bilateral agreements, non-governmental orga-
nisations and specific institutions, and/or professional
societies. The developing countries also benefited from
many international private initiatives, specifically phi-
lanthropists and other private sponsors, as well as
intergovernmental programmes.
As a result, there has been a significant increase in
clinical pharmacology activities in many developing
countries due to this international collaboration. For in-
stance, in Serbia, there was an increased demand for
clinical pharmacology services whereby the number of
therapeutic consultations rose from less than 150 per
year in 1995, to over 450 in 2003 [19]. From 1995 to
2006, the percentage growths in number of clinical trials
was 200% for Africa, 400% for Asia, 800% and 1000% for
Latin America [20]. In Russia alone, the number of clinical
trials increased from 62 clinical trials run in 315 sites in
2003, to 158 clinical trials run in 863 sites in 2006 [21].
Nevertheless, there is still a need for improvement in clin-
ical pharmacology programmes through increased local
and international support.
The disease burden
The disease burden is a major determinant of the amount
and type of medicines required by a given community,and this, in turn, determines the scale of clinical pharma-
cology services required to ensure rational use of these
medicines. From the survey, 60% of respondents indicated
that they had adequate number of patients’ disease profile
to enable training of clinical pharmacologists (Figure 1D).
Although this was a subjective question, the pilot study
had shown that respondents understood they were to
consider the number of patients and variety of disease
conditions in their responses. Nevertheless, 60% is low,
and this was most probably because the ‘disease burden’
in these countries is characterised by disease endemics
rather than ‘disease-variety’ which the medical school
seeks to meet its training requirements.
According to the UNAIDS (2008) report on the global
AIDS epidemic, the HIV/AIDS, tuberculosis, malaria, and
cardiovascular diseases were the leading causes of morbid-
ity and mortality in the developing world [22]. They were
characterized by an increased number of patients without
treatment, an urgent need to increase number of patients
on treatment, a need to provide lifelong therapy, a need to
treat resistant cases and the inadequacy of funding.
Specifically, by end of 2010, there were 2.7 million
new cases of HIV world-wide, of which 70% (1.9 million)
were from sub-Sahara Africa [23]. Furthermore, the HIV/
AIDS-related deaths between 2001 and 2010 increased
more than 10-fold in the Eastern Europe and Central Asia,
by 60% in the Middle East and North Africa, and more
than doubled in East Asia. Regarding the need to treat
more patients, only 20% of 34 million people with HIV/
AIDS were on treatment. On the other hand, the tubercu-
losis epidemic posed a serious challenge to the developing
world. In 2009, all the 22 high-tuberculosis-burdened coun-
tries were from the developing world, and they accounted
for over 80% of the new cases of tuberculosis [24]. Worst
still, the 27 countries with multi-drug resistant-tuberculosis
were from the developing world, and they accounted for
84% of the new cases of multi-drug resistant-tuberculosis.
Regarding malaria, in 2010, approximately 81% of the
new malaria cases were in Africa and 13% were in the
South-East Asia, and 91% of malaria deaths were in Africa
[25]. It was estimated that the financial requirement for
tuberculosis control is short by $1 billion dollars, while
that for malaria is short by $3 billion dollars.
In general, this information shows that the developing
world is still characterised by a high disease burden as
indicated by several disease epidemics, and this is as-
sociated with increased use of medicines with the
compounding requirements of rational prescribing and
appropriate therapeutic monitoring, all of which require
the expertise of a clinical pharmacologist.
Economic growth
Economic growth was a major determinant of progress
in clinical pharmacology development because it enabled
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care facilities, attract and retain expertise, and increased
availability of medicines. The best examples are the emer-
ging markets of Eastern Europe where 86% of the countries
had recognised clinical pharmacology as a specialty [26].
Since medical schools are in close association with
teaching hospitals where most clinical pharmacology
programmes are run, a comparison of the number of
medical schools in developing and developed countries
every 20 years since 1900 was made. This was then
related to the level of development of clinical pharmacol-
ogy programmes in the respective countries or regions. Of
note, the WHO defines a medical school as ‘any training
institution for health professionals’ and this includes
schools of medicine, pharmacy, nursing and allied health
sciences.
It was observed that, although presence of a medical
school in a country or region was a pre-requisite to the
existence of clinical pharmacology, the number of medical
schools in a country did not correlate with the level of
advancement in clinical pharmacology practice. Clinical
pharmacology is well advanced in the United Kingdom,
the United States of America and Germany, countries
where the number of medical schools has remained
consistently low for the past 100 years, and yet, the discip-
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Figure 2 Medical schools and clinical pharmacology development. Th
100 years in the developed (A), fast developing (Brazil, Russia, India, Chinamany new medical schools have been built in the past
50 years (Figure 2).
Specifically, most of the medical schools in the devel-
oped countries were built before 1900. By the year 1900,
Germany had 19 medical schools, the United Kingdom
had 20, the United State of America 53 and Japan 8, and
there were virtually no new medical schools after 2000
in each of these countries (Figure 2A). On the contrary,
both, the fast developing countries (Brazil, Russia, India
and China; BRIC) and the less developed countries, had
virtually no medical school before 1900 (Figure 2B and
2C). Medical schools in these countries were built after
1900: viz; in the BRIC countries, 234 new medicals schools
were built between 1940 to 1960, and 164 between 1960
to 1980, while in the less developed countries, 174 new
medical schools were built between 1960 to 1980 and 176
between 1980 to 2000.
Whereas by 2007 the number of medical schools in
Germany, the United Kingdom, the United States of
America and Japan increased only to double digits (19,
7, 82 and 75, respectively), the BRIC countries had a
total of 629 medical schools (276 in China, 154 in India,
78 in Brazil, 67 in Russia and 54 in Mexico), while the
less developed countries had a total of 528 medical
schools (257 in Asia [excluding China and India], 101 in
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Figure 3 An illustration of formulation of the policy for rational
use of medicines (R.U.Med.) in relation to other health care
policies at national levels. Key: Access = Access policy; DRA = Drug
Regulatory Authority; IPR = Intellectual property regulations; NHP =
National Health Plan; NMP = National Medicines Policy; PRICE =
pricing policy; QC = quality control; Supply = distribution policy.
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of medical schools that determine the development of
clinical pharmacology, but most probably, the activities
within these facilities. This is because these facilities were
built to meet other priorities where clinical pharmacology
was not included from the onset.
Nevertheless, the developing world exhibited a remark-
able increase in the number of medical training facilities
in the past 50 years, along with increased clinical pharma-
cology activities, particularly pharmacology training. This
implies that despite the lack of clinical pharmacologists,
there are professionals performing such work within these
countries. This poses a question as to whether the current
definition of a ‘clinical pharmacologist’ which emphasizes
the training background of a specialist physician is univer-
sally applicable. As such, the claim that clinical pharma-
cology in the developing countries is still in infancy may
be wrong because it ignores the reality that the profes-
sionals/practitioners in these countries are the clinical
pharmacologists.
The drug situation
The ‘drug situation’ refers to the extent of utilisation of
medicines to combat the disease burden through imple-
mentation of appropriate health care and medicines
policies. In the developing world, the drug situation is
characterised by severe drug shortages due to, among
other things, wide spread drug misuse, limited access
to drugs due to unaffordable cost and/or unavailability,
too many unnecessary drugs, a complex medicine supply
system and inadequate information to patients, etc., [27].
This situation was well expressed in the findings of the
current survey. Nevertheless, all these problems can be
addressed by developing appropriate medicines policies,
which includes the policy on the ‘rational use of
medicines’.
Formulation and implementation of the fundamental
policies of health-care
The major function of clinical pharmacologists is promo-
tion of the rational use of medicines [28,29]. However,
because implementation of the policy on rational use of
medicines is guided by the national health care policies,
clinical pharmacologists need to be part of the teams
formulating these policies to ensure that they articulate
with the policy on rational use of medicines (Figure 3).
Such polices in include: A national health plan, a national
medicine policy, a drug regulatory authority, a medicine
supply policy, an access to medicine policy, a policy on
rational use of medicines, a drug financing or pricing
policy, a policy on production and sale of medicines, and
a policy on intellectual property rights.
Regarding implementation, Table 2 illustrates the pro-
portion of countries by income group that had establishedseven of the above mentioned fundamental policies of
health-care by 2007. Along side each policy are the
respective performance indicators. Overall, 70% to 94% of
low income countries had established (written) the health
care policies that are fundamental to the development of
clinical pharmacology (i.e., a national health plan, a drug
regulatory authority, and policies on medicines’ financing,
supply, production and sales), and these percentages were
not far from the corresponding values of the high income
countries. However, the respective performance (or imple-
mentation) indicators for these policies in the low income
countries lagged behind those of the high income coun-
tries. For instance, regarding the national health plan, less
than 50% of the low income countries undertook a drug-
situation analysis, prescribing audit’ and ‘evaluation of
access to health care’. Also, the indicators for imple-
mentation of the sub-policies under the drug regulatory
authority such as pharmacovigilance (50%) and quality
control (68%) were still inadequate. Access to medicines
was less than 20% in low income countries versus 75%
in high income countries, while the medicines financing
policy was only successful for anti-tuberculosis drugs, with
research & development scoring an abysmal 16%.
Formulation and implementation of the policy for ‘rational
use of medicines’
From the afore-mentioned policies, more focused or sub-
ject specific policies are drawn to guide policy implemen-
Table 2 Comparison of the proportion (%) of countries that attained a particular policy or indicator in low, mid and
high income countries by 2007 [30]
WHO-countries income category
Parameter/Indicator Low income Mid-income High income
1. National Medicine Policy (NMP) 94% 84% 74%
Monitoring: Undertook assessment/audit of:
• National assessment of NMP 80% 65% 81%
• Pharmaceutical/Drug situation 37% 48% 69%
• Prescriptions audit 39% 46% 71%
• Access 50% 52% 72%
2. Drug Regulatory Authority (DRA) 89% 85% 97%
• Marketing authorization of Medicines 88% 84% 94%
• Licensing of manuf., imp./expt. (av.) 91% 91% 99%
• Licensing of prescribers & pharmacies 94% 99% 100%
• Pharmacovigilance (ADR) 50% 64% 67%
• Quality control system in place 68% 69% 96%
3. Access to essential medicines: patients within 1-hr walking distance to a clinic, 2003
• Very low Access (< 50%) 31% 6% 0%
• Low-Medium access (50 – 80%) 56% 38% 25%
• Medium-High access (81-95%) 10% 31% 0%
• Very high Access (< 95%) 2% 25% 75%
4. Medicine financing and/or pricing policy 93% 100% 100%
i) With health insurance policy? Medicines received for free:
• All medicines 35% 59% 55%
• Malaria medicines 59% 72% 47%
• Tuberculosis medicines 100% 92% 94%
ii) Monitoring medicine retail prices:
• Public sector 40% 58% 77%
• Private sector 36% 49% 78%
• NGO sector 17% 33% 71%
5. Medicines supply policy
• Procurement policy for Ess. Meds 74% 90% 92%
6. Production and sale of medicines
• R&D of new active substances 16% 27% 57%
• Repackaging of finished dos-forms 83% 78% 81%
• National legislation + TRIPS 55% 76% 86%
7. Rational use of medicines
Key: ADR, adverse drug reactions; AMR, antimicrobial resistance; CME, continuing medical education; DTC, drug therapeutics committees; Ess. Meds, essential
medicines; HIC, high income countries; LIC, low income countries; MIC, middle income countries; NGO, non-government organisation; NMP, National medicine
policy; R&D, research and development; TRIPS, trade-related aspects of intellectual property rights.
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are the leading professionals in the implementation of
the policy on ‘rational use of medicines’. This is also
emphasized in the WHO recommendations that countries
must encourage or ensure more appropriate (rational)
use of medicines [29,31] by; establishing a national drug
regulatory authority, formulating standard treatment
guidelines, selecting an essential medicines’ list, setting updrug or pharmaceutical therapeutics committees, promot-
ing training in good prescribing practices, enforcing con-
tinuing medical education, promoting prescribing audit
or accredited standard of health care, providing unbiased
medical information through medicines information cen-
tres and national drug formularies, promoting community
education campaigns about medicines and patient package












Figure 4 An illustration of the implementation of the policy for rational use of medicines (R.U.Med.) through its sub-policies at the
peripheral level. Key: CME = Continuing medical education; EML = Essential Medicines List; MIC =Medical and Poison Information centre;
NDF = National drug formulary; PTC = Provincial Therapeutic committees; PV = Pharmacovigilance; STG = Standard Treatment Guidelines.
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promotion or advertising as adopted in resolution WHA
41.17, and advocate for adequate funding for health care.
Regarding implementation, Table 3 shows the propor-
tion of countries by ‘country income group’ that had
established nine of the sub-policies for promoting rational
use of medicines by 2007. They are also accompanied by
the respective indicators for implementation. Whereas
the policy documents for promotion of rational use of
medicines were available in more than 80% of the low
income countries, their respective indicators for implemen-
tation were not impressive. Specifically, the proportion
of low income countries with programmes for each of
the nine indicators illustrated in Table 3 was far lower
than that of high income countries. However, some of
the respective performance indicators though low, were
promising. For instance, the proportion of low income
countries with appropriate prescribers at primary health
care level, promoting generic substitution, and regulating
medicines advertisement were almost similar to that of
high income countries (> 85%).
Nevertheless, the poor implementation of the policy
on rational prescribing should be expected in view of the
fact that implementation of the fundamental health-carepolicies was also low. The current drug situation in low
income countries can be better appreciated when one
considers the trend of events over the past 20 or more
years. In fact, Figure 5 shows that policy formulation in
the low income countries has been a fast process. The
proportion of low income countries with a national
medicines policy increased from less than 10% in 1985
to 94% in 2007, while the proportion with drug regula-
tory authorities increased from less than 40% in 1999 to
89% in 2007, and those with an essential medicines list
increased from less than 10% in 1985 to 100% in 2007
[32-34]. Likewise, some indicators for policy implemen-
tation improved dramatically whereby the proportion of
low income countries revising their essential medicines
list every five years increased from less than 10% in
1985, to over 80% in 2007 (Figure 5).
Unfortunately, by 2007, the indicators for implementa-
tion of sub-policies that ensure rational use of medicines
were not different from those of 2003 (Table 4) [31,35].
Whereas the increase in adverse drug reaction reporting
(15%) and availability of standard treatment guidelines at
national level (22%) were appreciated, these two indicators
reflect availability rather than performance. In general, the
required policy documents for health-care and rational
Table 3 Comparison of the proportion (%) of countries that attained a particular policy or indicator for rational use of
medicines in low, mid and high income countries in 2007 [45]
WHO-countries income category
Parameter/Indicator Low income Mid-income High income
1. Standard Treatment Guidelines (STG) 89% 75% 80%
2. Essential Medicines list (EML): 100% 86% 68%
• EML-Updated in <5 years 81% 74% 41%
3. Drug Therapeutics Committees (DTC): 38% 58% 74%
4. Prescribing policy or supervision/monitor prescribing
i) Prescribers at primary care level in public sector
• Doctors 98% 99% 100%
• Nurses 89% 60% 66%
• Pharmacists 37% 16% 3%
• Other 23% 9% 0%
ii) Policy on generic medicines in public sector
• Obligatory use of generics 63% 62% 18%
• Generic substitution allowed 85% 87% 77%
• Incentives for prescribing generics 48% 26% 67%
iii) Prescriptions audit 39% 46% 71%
iv) Strategy for AMR containment 24% 46% 73%
5. Education and Training in CP: undergraduate and post graduate education (Includes training on EML, STG, pharmacotherapy & Rational
prescribing)
• Doctors 62 ± 3.7% 73 ± 7.1% 88 ± 17.4%
• Nurses 58 ± 10.8 57 ± 3.0% 73 ± 6.0%
• Pharmacists 62 ± 11.5% 60 ± 6.7% 80 ± 13.3%
• Other 33 ± 5.3% 32 ± 6.2% 36 ± 5.3%
6. Continuing Medical Education (CME): Obligatory CME for:
• Doctors 51% 54% 70%
• Nurses + paramedics 53% 44% 65%
• Pharmacists 56% 51% 57%
7. Provision of information on Medicines:
• Med. Information Centres 36% 52% 75%
• Medicines formulary 57% 69% 70%
8. Public/Consumer education and information on medicines
• Education campaigns (A/biotic use) 44% 52% 62%
• Other rational medicine use topics 60% 56% 73%
9. Medicine promotion & advertising:
• Regulate Drug prom/advertisement 85% 86% 100%
Key: AMR, antimicrobial resistance; CME, continuing medical education; CP, clinical pharmacology; DTC, drug therapeutics committees; EML, essential medicines;
HIC, high income countries; LIC, low income countries; MIC, middle income countries; STG, standard treatment guidelines.
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ing countries, but their implementation remained poor.
Traditional medicines
With the majority of people in developing countries using
traditional medicines for their health-care needs and
concerns [36-38], there has been a growing recognition
of traditional medicines as indicated by a worldwideincrease in the number of countries with policies for
regulation of traditional medicines, from 15 countries in
1986 to 110 in 2007 [39]. However, several challenges in
the regulation of traditional medicines have been encoun-
tered. Specifically, the non-standardized classification
of traditional medicines has made it more difficult to
impose strict rules on their use. Traditional medicines


























Figure 5 The proportion (%) of low income countries (LIC) that have formulated the relevant policies from 1985 to 2007 [30]. Key: DRA:
Drug Regulatory Authority; EML = Essential Medicines List; EML-Rev. = Essential Medicines List-Revision; NMP National Medicines Policy.
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peutic agents, or even simply as medicines or as a food-
stuff [40]. Also, since one product may be used for several
diseases, it is may be sold as a prescription or over-the-
counter medicine for self-medication, home remedies,
dietary supplements, health foods, functional foods or
by some other title [41]. Therefore, depending on the
level of sophistication of the regulatory framework, aTable 4 Indicators for policy implementation: comparison
of the proportion (%) of low income countries that
implemented the respective sub-policies for promoting
rational use of medicines in 2003 and 2007 [30]
Year 2003 2007
Availability of STGs
• STGs at National level 67.3% 89%
• STGs at Primary Health level 75% 72%
• NMF for EML 56.4% 57%
Education and information
• EML in Med-Curriculum 67.3% 65.9%
• STG in Med-Curriculum 62.2% 59.5%
• CME for doctors 37.7% 51.1%
• Provided Med. Inform. to prescribers 32.1% 36.2%
• Public Education on Antibiotics 37.0% 44.4%
Key policies and regulations to promote rational drug use
• ADR monitoring 32.7% 50.0%
• DTC in General Hospitals 38.8% 41.5%
• DTC in Regional Hospitals 36.2% 31.4%
• AMR-policy 23.6% 20.0%
Key: ADR, adverse drug reactions; AMR, antimicrobial resistance; CME,
continuing medical education; DTC, drug therapeutics committees; EML,
essential medicines list; LIC, low income countries; NMF, national medical
formulary; STG, standard treatment guidelines.single medicinal plant may be simultaneously defined and
regulated under several different regulatory instruments.
The WHO advises that countries must formulate national
standards, policies and regulations governing the produc-
tion and use of traditional medicines to promote and
maintain good practice among appropriately-educated
producers and practitioners for the benefit of the popu-
lation [37,42].
Already, several clinical pharmacologists in the devel-
oping countries are involved in the establishment of
appropriate specifications and standards for traditional
medicines that will serve as the basis for consistency,
quality control and the verification of safety [43-45], as
well as establishment of a post-marketing surveillance
system for the evaluation of potential toxicity and herb-
herb/herb-drug interactions [32]. For instance, in China,
25% of the medical schools are for Chinese traditional
medicines [26], and traditional herbal medicinal prepa-
rations constituted between 30% and 50% of the total
consumption of medicines in 2005 [39].
The trend
A persistent need for clinical pharmacology
In a nut shell, there are several on-going clinical pharma-
cology activities in the developing world, but these ac-
tivities are at different stages in the different countries
depending on the level of economic advancement. The
persistent epidemics of new and old diseases have led to
increased demand for more medicines, which in turn,
has increased the requirement for clinical pharmacology
services. In the same perspective, the wide scope of clinical
pharmacology activities enumerated here may be counter-
productive by overstretching and thereby contributing to
the scarcity of clinical pharmacologists. This is an appro-
priate concern, but this report was not on ‘how to utilize
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need not be full time employees in some of the roles indi-
cated. In fact, some of the clinical pharmacology activities
enumerated here, e.g., drug regulatory authority and
national policy formulation, are run by other health
care professionals whereby clinical pharmacologists only
serve as temporary advisers. Therefore, the use of clinical
pharmacologists in some of the clinical pharmacology
activities will be determined by the availability of other
experts for the respective tasks.
Task shifting
Although the number of medical schools do not predict
advancement in clinical pharmacology activities, there
has been considerable progress in developing clinical
pharmacology through training, and running of clinical
pharmacology services, particularly by non-governmental
organisations such as the WHO and UNAIDS. In the
WHO’s programmes and other non-governmental organi-
sations, clinical pharmacologists at their headquarters
(located in the developed world) participate in the
formulation of the clinical pharmacology policies and
programmes, after which these programmes are run by
professionals other than clinical pharmacologists, i.e.,
‘task shifting’. Specifically, ‘task shifting’ is where some
of the allied health professionals (non-medical doctors)
are trained in disease-specific therapeutics, e.g., HIV,
tuberculosis, etc., to enable them prescribe some medi-
cines under particular circumstances (Figure 6). ‘Task
shifting’ is a challenging concept that requires careful
planning in the selection, training and monitoring of
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Figure 6 An illustration of the level of the preferred clinical
pharmacologist physician (red box) with regard to level of
training (masters), service delivery and task shifting (purple).
Key: 2ry/3ry level = Secondary or tertiary level; HCW = Health care
workers; HC-workers = Health care workers; Home B-care = Home
based care; M.B.Ch.B. = Bachelor of Medicine & Bachelor of surgery;
M.Med. = Master of Medicine; Ph.D. = Doctor of philosophy.this is beyond the scope for this report. However, success
in ‘task shifting’ has been made possible by the fact that,
currently, many developing countries have developed and
implemented several drug policies and guidelines for
promoting rational drug use, which forms the basis for
training other professionals.Relevant training
For developing countries, the current training of an in-
ternationally recognised clinical pharmacologists with a
Ph.D. takes too long. Such training often veers off the
local requirements, and ventures into irrelevancy by
emphasising highly specialised research over service de-
livery. Clinical pharmacology training for the developing
countries needs to be modified to address local relevancy
and within the optimum time. Therefore, it is no wonder
that, currently, several developing countries have turned
away from doctoral studies as the primary qualification
for a clinical pharmacologist, to producing a physician
in clinical pharmacology, whereby, after the primary
medical degree (M.B.Ch.B.) and at least two years of
practice, the candidate undertakes a four year training
programme in clinical pharmacology, and graduates
with a Masters’ degree (M. Med.) or fellowship in clin-
ical pharmacology (Figure 6). These professionals are
employed in tertiary and peripheral hospitals where
the government has created posts along side those of
other clinical specialities. Even then, this does mean
that doctoral studies are irrelevant. Therefore, as for
other clinical specialties, these specialist clinical phar-
macologists form a pool from which Ph.D. aspirants
can be selected.Advocacy
There is a need to promote recognition of clinical
pharmacology by high advocacy both locally and
internationally, particularly by intensifying IUPHAR’s
programmes in this regard. Intervention strategies need
to take the stakeholders’ interests into account so as to
ensure cooperation. For instance, more government
support is likely if the focus is on service based clinical
pharmacologists, while international support is more
likely with advanced training usually doctoral or research
fellowship studies. Clinical pharmacology services should
be extended to peripheral hospitals, and play a leading
role in the formulation and implementation of drug
policies. Besides clinical pharmacology consultation,
the afore mentioned clinical pharmacology physicians
should also provide special courses in clinical phar-
macology (or rational prescribing) for medical students
and other health workers as part of the continuing
medical education.
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Circumstances in the developing countries foster pro-
motion of ‘a specialist clinical pharmacologist’ and ‘task
shifting’ for some endemic diseases as the most appropri-
ate strategies to meet the current and future challenges to
rational use of medicines in these countries. This implies
that clinical pharmacology in developing countries is
advancing in a different way to that in the developed
world and that this does not, in any way, mean poor
quality or no progress. Continuing support for these
efforts will go a long way in promoting improved health
for all.
Competing interests
The author declares that he had no competing interests.
Authors’ information
Prof. Andrew Walubo M.B.Ch.B., M. Phil., M.D., MBA, FCP. Prof. Walubo is a
chief clinical pharmacologist at Universitas academic hospital, and head of
department of pharmacology of the University of the Free State. He
completed his medical degree at Makerere University in Uganda, master’s
studies in Hong Kong, doctoral studies at the University of Cape Town and a
postdoctoral fellowship in the Division of Clinical Pharmacology at Vanderbilt
University USA.
Prof. Walubo has been instrumental in promotion of clinical pharmacology
for a long time. He is a fellow of the American College of Clinical
Pharmacology, and founder and ‘Associate Member’ of the ‘The college of
Clinical Pharmacologists of South Africa (CCP SA) which governs the training
and examination of clinical pharmacology specialists in South Africa. He is a
member of the Senate of the Colleges of Medicine of South Africa (CMSA),
the Medicines Control Council (MCC; South Africa’s drug regulatory
authority) and the Executive committee of the South African Society for
Basic and Clinical Pharmacology (SASBCP), to mention but a few. He is a co-
author to the 2012 World Health Organization’s (WHO) publication on ‘Clinical
Pharmacology in Health Care, Teaching and Research (http://www.who.int/
medicines/areas/quality_safety/safety_efficacy/OMS-CIOMS-Report-20120913v4.
pdf); to the IUPHAR ‘position statement on Clinical Pharmacology’ in 2010
(Basic Clin Pharmacol Toxicol 2010, 107: 531–559); and a leading author to
the recent article (S. Afr.Med.J. 2013;103 (3):150–151) entitled ‘Clinical
pharmacology becomes a specialty in South Africa’. Among other things,
Andrew is involved in assisting/organising clinical pharmacologists in some
countries in Africa.
Acknowledgements
The author is grateful to all colleagues that helped to reach out in their
respective institutions.
Received: 3 June 2013 Accepted: 25 September 2013
Published: 28 September 2013
References
1. Turner P (Ed): Proceedings of plenary lectures, symposia and therapeutic
sessions of the First World Conference on Clinical Pharmacology and
Therapeutics, 3–9 August 1980. London, UK: Clinical Pharmacology &
therapeutics: MacMillen Publishers; 1980.
2. Fraser HS: Clinical pharmacology in developing countries. Br J clin
Pharmacol 1981, 11:457–459.
3. Richens A, Routledge A: Essentials of clinical pharmacology for education
and research in developing countries. Br J clin Pharmacol 1984, 18:123–126.
4. Gyapong JO, Ofori-Adjei D: Capacity building for relevant health research in
developing countries; 2009. http://www.inclentrust.org/uploadedbyfck/file/
compile%20resourse/new-resourse-dr_-vishal/Capacity%20Building%20for%
20Relevant%20Health%20Research%20in%20Developing%20Counties.pdf.
5. International scholarship: for non-degree, undergraduate, postgraduate, PhD
and post-doctoral students (website). http://scholarization.blogspot.com/
2011/01/phd-scholarship-in-medical-science.html.
6. Manabe YC, Katabira E, Brough RL, Coutinho AG, Sewankambo N, Merry C:
Developing independent investigators for clinical research relevant forAfrica. Health Res Policy Syst. 2011, 9:44–45. http://www.health-policy-
systems.com/content/pdf/1478-4505-9-44.pdf.
7. Matee MI, Manyando C, Ndumbe PM, Corrah T, Jaoko WG, Kitua AY, et al:
European and developing countries clinical trials partnership (EDCTP):
the path towards a true partnership. BMC Public Health 2009, 9:249.
doi:10.1186/1471-2458-9-249.
8. Tomatis C, Taramona C, Rizo-Patrón E, Hernández F, Rodríguez P, Piscoya A,
et al: Evidence-based medicine training in a resource-poor country, the
importance of leveraging personal and institutional relationships. J Eval
Clin Pract 2011, 17:644–650. doi:10.1111/j.1365-2753.2011.01635.
9. Sadavongvivad C: Challenge of clinical pharmacology in developing
countries. J Clin Pharmacol 1980, 20:621–624.
10. Laing RO, Hogerzeil HV, Ross-Degnan D: Ten recommendations to improve use
of medicines in developing countries. Health Policy Planning 2001, 16:13–20.
11. Blaschke TF: Global Challenges for clinical pharmacology in the
developing world. Clin Pharmaco Ther 2009, 85:579–581.
12. Nielsen L: Classifications of countries based on their level of development: How
it is done and how it could be done. IMF working paper; 2011. http://www.
imf.org/external/pubs/ft/wp/2011/wp1131.pdf.
13. World Bank list of economies: World Bank list of economies; 2012.
http://librarians.acm.org/sites/default/files/world%20bank%20List%20of%
20Economies%20(as%20of%20July%202012).pdf.
14. Nulty DD: The adequacy of response rates to online and paper surveys:
what can be done? Assess Eval Higher Educ 2008, 33:301–314. doi:10.1080/
02602930701293231. http://www.uaf.edu/files/uafgov/fsadmin-nulty5-19-10.pdf.
15. Suryawati S: Contribution of clinical pharmacology to improve the use of
medicines in developing countries. Int J Risk Safety Med 2005, 17:57–64.
16. Abernethy D, Birkett D, Brøsen K, Cascorbi I, Gustafsson LL, Hoppu K, et al:
Clinical Pharmacology in health care, teaching and research. In Edited by
Orme M, Sjöqvist F, Birkett D; 2012. http://www.who.int/medicines/areas/
quality_safety/safety_efficacy/OMS-CIOMS-Report-20120913v4.pdf.
17. Birkett D, Brøsen K, Cascorbi I, Gustafsson LL, Maxwell S, Rago L, et al:
Clinical pharmacology in research, teaching and health care:
Considerations by IUPHAR, the International Union of Basic and Clinical
Pharmacology. Basic Clin Pharmacol Toxicol 2010, 107:531–559. doi:10.1111/
j.1742-7843.2010.00602.
18. Walubo A, Barnes KI, Kwizera E, Greeff O, Rosenkranz B, Maartens G: Clinical
pharmacology becomes a speciality in South Africa. SAMJ 2013,
301:150–151.
19. Jankovic SM, Dragojevic’-Simic’ V, Milovanovic’ DR: Impact of clinical
pharmacology on health care: Serbian experience. Eur J Clin Pharmacol
2005, 61:787–788.
20. Kline D: Clinical Trials in Latin America - White paper; 2001. http://www.fast-
track.com/pdfs/ClinicalTrialsLatinAmerica.pdf.
21. Synergy Research Group: Clinical trials in Russia. Orange paper. No. 1/2007.
Overview and Year; 2006. http://www.appliedclinicaltrialsonline.com/applied
clinicaltrials/data/articlestandard//appliedclinicaltrials/222007/430480/article.pdf.
22. UNAIDS: Report on the global AIDS epidemic, 2008. Geneva: UNAIDS; 2008. http://
www.unaids.org/en/dataanalysis/knowyourepidemic/epidemiologypublications/
2008reportontheglobalaidsepidemic/. ISBN 978 92 9 173711 6.
23. World Health Organization: Global HIV/AIDS response - epidemic update and health
sector progress towards universal access, Progress Report 2011. Geneva: WHO/
UNICEF/UNAIDS; 2011. http://www.unaids.org/en/media/unaids/contentassets/
documents/unaidspublication/2011/20111130_ua_report_en.pdf.
24. World Health Organization report: Global tuberculosis control. Geneva: WHO;
2010. http://www.doh.state.fl.us/disease_ctrl/tb/trends-stats/Fact-Sheets/US-
Global/WHO_Report2010_Global_TB_Control.pdf. ISBN 978 92 4 156406 9.
25. World Health Organization: Global malaria programme. World malaria report:
2011. Geneva: WHO; 2011. http://apps.who.int/iris/bitstream/10665/44792/2/
9789241564403_eng_full.pdf. ISBN 978 92 4 156440 3.
26. World Health Organization: World directory of medical schools. University of
Copenhagen. The AVICENNA directory of medicine; 2010. http://www.who.
int/hrh/wdms/en/.
27. Smith AJ: Unfinished business: clinical pharmacology and world health.
Int J Risk Safety Med 2005, 17:65–71.
28. World Health Organization: The rational use of drugs. Geneva: Report of the
conference of experts, Nairobi, 25–29 November 1985; 1987. http://apps.
who.int/medicinedocs/documents/s17054e/s17054e.pdf.
29. World Health Organization: Promoting rational use of medicines: Core
components. Geneva: WHO Policy Perspectives on Medicines, No.5; 2002.
http://apps.who.int/medicinedocs/pdf/h3011e/h3011e.pdf.
Walubo BMC Pharmacology and Toxicology 2013, 14:49 Page 15 of 15
http://www.biomedcentral.com/2050-6511/14/4930. Noller BN, Myers S, Abegaz B, Singh MM, Kronenberg F, Bodeker G: Global
forum on safety of herbal and traditional medicine: July 7, 2001, gold
coast, Australia. J Altern Complement Med 2001, 7:583–601.
31. World Health Organization: The World Medicines Situation 2011: Rational
Use of Medicines. In The World Medicines Situation 2011: Rational Use of
Medicines. 3rd edition. Edited by Holloway K, van Dijk L. Geneva: WHO; 2011.
http://apps.who.int/medicinedocs/documents/s16874e/s16874e.pdf.
32. World Health Organization: Country pharmaceutical situations: Fact Book on
WHO Level 1 indicators 2007. Geneva: WHO Press; 2010. http://apps.who.int/
medicinedocs/documents/s16874e/s16874e.pdf.
33. World Health Organization: Using indicators to measure country
pharmaceutical situations; Fact Book on WHO Level I and Level II monitoring
indicators, 2003. Geneva: WHO Press; 2006. http://www.who.int/medicines/
publications/WHOTCM2006.2A.pdf.
34. World Health Organization: The World Medicines Situation. Geneva: WHO; 2004.
http://apps.who.int/medicinedocs/pdf/s6160e/s6160e.pdf..
35. World Health Organization: The world medicines situation 2011: Access to
care and medicines, burden of health care expenditures, and risk
protection: results from the world health survey. In Eds. A.K. Wagner, A.J.
Graves, S.K. Reiss, R. LeCates, F. Zhang and D.s Ross-Degnan. 3rd edition.
Edited by Holloway K, van Dijk L. Geneva: WHO; 2011. http://apps.who.int/
medicinedocs/documents/s16874e/s16874e.pdf.
36. World Health Organization: WHO Traditional medicine strategy 2002–2005.
Geneva: WHO/EDM/TRM/2002.1; 2002. http://apps.who.int/medicinedocs/
pdf/s2297e/s2297e.pdf.
37. World Health Organization: Guidelines on registration of traditional medicines
in the WHO African Region. Brazzaville: World Health Organization Regional
Office for Africa; 2004. (AFR/TRM/04.1). http://whqlibdoc.who.int/afro/2004/
AFR_TRM_04.1.pdf.
38. UNAIDS: AIDS Epidemic Update: December 2003. Geneva: WHO; 2003.
http://data.unaids.org/publications/irc-pub06/jc943-epiupdate2003_en.pdf.
39. World Health Organization: In The World Medicines Situation 2011: Traditional
Medicines: Global Situation, Issues and Challenges. 3rd edition. Edited by
Robinson MM, Zhang X. Geneva: WHO; 2011. http://digicollection.org/hss/
documents/s18063en/s18063en.pdf.
40. World Health Organization: Report of the Regional Meeting on Traditional
Medicine and Herbal Medicines. Guatemala City, 18–20 February 2003.
Geneva; 2003.
41. World Health Organization: National policy on traditional medicine and
regulation of herbal medicines: Report of a WHO global survey. Geneva: WHO;
2005. http://apps.who.int/medicinedocs/pdf/s7916e/s7916e.pdf.
42. World Health Organization: Resolution WHA62.13. Geneva: Traditional
medicine; 2009. http://apps.who.int/gb/ebwha/pdf_files/WHA62-REC1/
WHA62_REC1-en-P2.pdf.
43. Li S, Han Q, Qiao C, Song J, Cheng CL, Xu H: Chemical markers for the
quality control of herbal medicines: An overview. Chinese Med 2008, 28:7.
44. World Health Organization: Guidelines on minimum requirements for the
registration of herbal medicinal products in the Eastern Mediterranean Region.
Cairo: World Health Organization Regional Office for the Eastern
Mediterranean; 2006. WHO-EM/EDB/048/E.
45. World Health Organization: Guidelines for the regulation of herbal medicines
in the South-East Asia Region. New Delhi: World Health Organization
Regional Office for South-East Asia; 2004. SEA-Trad. Med.-82.
doi:10.1186/2050-6511-14-49
Cite this article as: Walubo: The current status and trend of clinical
pharmacology in developing countries. BMC Pharmacology and
Toxicology 2013 14:49.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
